Drug intelligence / Profile preview

AZD5069 + ketoconazole

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD5069 + ketoconazole is a combination of AZD5069, a selective small-molecule antagonist of the chemokine receptor CXCR2, and ketoconazole, a potent oral antifungal agent and strong CYP3A4 inhibitor. AZD5069 inhibits neutrophil migration by blocking CXCR2, aiming to reduce inflammation in diseases like severe asthma and COPD. Ketoconazole, though primarily an antifungal, is administered in this context to study its effect as a CYP3A4 inhibitor on AZD5069 pharmacokinetics. Co-administration increases AZD5069 systemic exposure (AUC and Cmax) by decreasing its metabolism.

Other names: ketoconazole

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)

Beyond the preview

Go deeper on AZD5069 + ketoconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD5069 + ketoconazole.

Explore the full profile